bloodjourГематология и трансфузиологияRussian journal of hematology and transfusiology0234-57302411-3042ООО Издательский дом «Практика»10.35754/0234-5730-2026-71-2-188-201bloodjour-762Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCASE REPORTSПриобретенная гемофилия А, вызванная приемом клопидогрелаAcquired hemophilia a induced by clopidogrelhttps://orcid.org/0000-0001-8818-8949ГалстянГ. М.GalstyanG. M.

Галстян Геннадий Мартинович, доктор медицинских наук, заведующий отделением реанимации и интенсивной терапии; профессор кафедры анестезиологии и реаниматологии

125167, г. Москва

 117997, г. Москва

Gennadiy M. Galstyan, Dr. Sci. (Med.), Head of the Resuscitation and Intensive Care Department; Professor of Department of Anesthesiology and Intensive Care

125167, Moscow

117997, Moscow

gengalst@gmail.comhttps://orcid.org/0009-0002-3984-3702КостюкД. Ю.KostyukD. Yu.

Костюк Дарья Юрьевна, аспирант отделения реанимации и интенсивной терапии

125167, г. Москва

Daria Yu. Kostyuk, Postgraduate Student, Resuscitation and Intensive Care Department

125167, Moscow

kostyuk.dash@yandex.ruhttps://orcid.org/0000-0003-1492-1735МамлееваС. Ю.MamleevaS. Yu.

Мамлеева Светлана Юрьевна, заведующая экспресс-лабораторией

125167, г. Москва

Svetlana Yu. Mamleeva, Head of Express-Laboratory

125167, Moscow

maml.s-yur@yandex.ruФГБУ «Национальный медицинский исследовательский центр гематологии» Министерства здравоохранения Российской Федерации; ФГБУ «Национальный медицинский исследовательский центр акушерства гинекологии и перинатологии им. академика В.И. Кулакова» Министерства здравоохранения Российской ФедерацииРоссияNational Medical Research Center for Hematology; National Medical Research Center for Obstetrics, Gynecology and PerinatologyRussian FederationФГБУ «Национальный медицинский исследовательский центр гематологии» Министерства здравоохранения Российской ФедерацииРоссияNational Medical Research Center for HematologyRussian Federation202617072026712188201Copyright © Галстян Г.М., Костюк Д.Ю., Мамлеева С.Ю., 20262026Галстян Г.М., Костюк Д.Ю., Мамлеева С.Ю.Galstyan G.M., Kostyuk D.Y., Mamleeva S.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.htjournal.ru/jour/article/view/762Введение

Введение. Двойная антитромбоцитарная терапия (ДАТТ) аспирином и ингибитором P2Y12-рецепторов тромбоцитов является одним из основных компонентов лечения и вторичной профилактики у больных, перенесших чрескожное коронарное вмешательство при остром инфаркте миокарда. Среди побочных эффектов ДАТТ геморрагические осложнения, обусловленные дезагрегантным действием препаратов. Меньше известно о геморрагических осложнениях при приеме клопидогрела, обусловленных коагуляционными нарушениями.

Цель

Цель: представить клиническое наблюдение приобретенной гемофилии А, возникшей у больного вследствие приема клопидогрела.

Основные сведения

Основные сведения. Больной 68 лет получал клопидогрел в рамках ДАТТ после чрескожного коронарного вмешательства. Через месяц у него возник выраженный геморрагический синдром, обусловленный появлением антител к фактору свертывания VIII (FVIII: C 1,5 %, ингибитор фактора VIII 61 БЕ). Отмена клопидогрела, гемостатическая терапия эптакогом альфа (активированным) и иммуносупрессивная терапия преднизолоном, циклофосфамидом и ритуксимабом позволили не только купировать геморрагический синдром, но и добиться эрадикации ингибитора.

Introduction

Introduction. Dual antiplatelet therapy (DATT) with aspirin and a platelet P2Y12 receptor inhibitor is one of the main components of treatment and secondary prevention in patients undergoing percutaneous coronary intervention in acute myocardial infarction. Among the side effects of DATT are hemorrhagic complications caused by the antiplatelet effect of the drugs. Less is known about hemorrhagic complications caused by coagulation disorders when taking clopidogrel.

Aim

Aim: to present a clinical case of acquired hemophilia A, which occurred in a patient as a result of taking clopidogrel.

Main findings

Main findings. A 68-year-old patient received clopidogrel as part of DATT after percutaneous coronary intervention. One month later, he developed a pronounced hemorrhagic syndrome caused by the appearance of antibodies to coagulation factor VIII (FVIII:C 1.5 %, factor VIII inhibitor 61 BU). The elimination of clopidogrel, hemostatic therapy with eptacog alpha (activated) and immunosuppressive therapy with prednisone, cyclophosphamide and rituximab allowed not only to stop the hemorrhagic syndrome, but also to achieve eradication of the inhibitor.

клопидогрелфактор VIIIингибиторприобретенная гемофилиярекомбинантный эптаког альфа (активированный)преднизолонциклофосфамидритуксимабclopidogrelfactor VIIIinhibitoracquired hemophiliarecombinant eptacog alpha (activated)prednisonecyclophosphamiderituximabReferencesБойцов С.А., Шахнович Р.М., Терещенко С.Н. и др. Особенности терапии ингибиторами P2Y12‐рецепторов тромбоцитов у пациентов с инфарктом миокарда по данным Российского регистра острого инфаркта миокарда — РЕГИОН–ИМ. Кардиология 2022. 2022;62(9):44–53. DOI: 10.18087/cardio.2022.9.n2278.Boytsov S.A., Shakhnovich R.M., Tereschenko S.N., et al. Features of antiplatelet therapy with P2Y12 receptor inhibitors in patients with myocardial infarction according to the Russian Register of Acute Myocardial Infarction REGIONMI. Kardiologiya. 2022. 2022;62(9):44–53 (In Russian). DOI: 10.18087/cardio.2022.9.n2278.Wadowski P., Eichelberger B., Kopp C., et al. Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy. О Cardiovasc Trans Res. 2017;10:359–67. DOI: 10.1007/s12265-017-9746-0.Wadowski P., Eichelberger B., Kopp C., et al. Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy. О Cardiovasc Trans Res. 2017;10:359–67. DOI: 10.1007/s12265-017-9746-0.Izaguirre-Avila R., Pena-Diaz A.D., Barinagarrementeria-Aldatz F., et al. Effect of Clopidogrel on Platelet Aggregation and Plasma Concentration of Fibrinogen in Subjects with Cerebral or Coronary Atherosclerotic Disease. Clin Appl Thromb Hemost. 2002;8(2):169–77.Izaguirre-Avila R., Pena-Diaz A.D., Barinagarrementeria-Aldatz F., et al. Effect of Clopidogrel on Platelet Aggregation and Plasma Concentration of Fibrinogen in Subjects with Cerebral or Coronary Atherosclerotic Disease. Clin Appl Thromb Hemost. 2002;8(2):169–77.Yusuf S., Fox K., Tognoni G., et al. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST‐Segment Elevation. New Engl J Med. 2001;345(7):494–502. DOI: 10.1056/NEJMoa010746.Yusuf S., Fox K., Tognoni G., et al. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST‐Segment Elevation. New Engl J Med. 2001;345(7):494–502. DOI: 10.1056/NEJMoa010746.Orok E., Adeniyi F., Akawa O. Dual Antiplatelet Therapy. In: Karcıoğlu O, Akarca FK, editors. Atrial Fibrillation — Diagnosis and Management in the 21st Century. 1st ed. Istanbul; 2022. DOI: 10.5772/intechopen.105139.Orok E., Adeniyi F., Akawa O. Dual Antiplatelet Therapy. In: Karcıoğlu O, Akarca FK, editors. Atrial Fibrillation — Diagnosis and Management in the 21st Century. 1st ed. Istanbul; 2022. DOI: 10.5772/intechopen.105139.Ye X., Shami J., Yan V., et al. Global antiplatelet sales trend: A focus on P2Y12 inhibitors from 2008 to 2018. Am Hear J Plus. 2021;4:100020. DOI: 10.1016/j.ahjo.2021.100020.Ye X., Shami J., Yan V., et al. Global antiplatelet sales trend: A focus on P2Y12 inhibitors from 2008 to 2018. Am Hear J Plus. 2021;4:100020. DOI: 10.1016/j.ahjo.2021.100020.Toms M. Haemophilia risk with clopidogrel. React Wkly. 2013;1471:3. DOI: 10.1007/s40278-013-6063-5.Toms M. Haemophilia risk with clopidogrel. React Wkly. 2013;1471:3. DOI: 10.1007/s40278-013-6063-5.Zhou Z., Xie H., Fan F., et al. Comparison of in-hospital net clinical outcomes of ticagrelor and clopidogrel in acute coronary syndrome patients stratified by CRUSADE score: findings from the CCC-ACS registry. Platelets. 2025;36(1):2570743. DOI: 10.1080/09537104.2025.2570743.Zhou Z., Xie H., Fan F., et al. Comparison of in-hospital net clinical outcomes of ticagrelor and clopidogrel in acute coronary syndrome patients stratified by CRUSADE score: findings from the CCC-ACS registry. Platelets. 2025;36(1):2570743. DOI: 10.1080/09537104.2025.2570743.Галстян Г.М., Полеводова О.А., Терехова И.В. и др. Применение тромбоэластографии, теста генерации тромбина и клоттинговых тестов для оценки эффективности гемостатической терапии рекомбинантным активированным фактором VII у больных с ингибиторной формой гемофилии. Российский журнал детской гематологии и онкологии. 2017;4(4):33–8. DOI: 10.17650/2311-1267-2017-4-4-33-38.Galstyan G.M., Polevodova O.A., Terekhova I.V., et al. The use of thromboelastography, thrombin generation test and clotting tests to evaluate the efficacy of hemostatic therapy with recombinant activated factor VII in hemophilia patients with inhibitor. Rossiyskiy Journal Detskoy Gematologii I Onkologii. 2017;4(4):33–8 (In Russian). DOI: 10.17650/2311-1267-2017-4-4-33-38.Галстян Г.М., Налбандян С.А., Сабиров К.Р. и др. Тактика лечения больной приобретенной гемофилией: непрерывная инфузия рекомбинантного активированного фактора свертывания VII и эрадикация ингибитора. Гематология и трансфузилогия. 2022;67(2):282–94. DOI: 10.35754/0234-5730-2022-67-2-282-294.Galstyan G.M., Nalbandyan S.A., Sabirov K.R., et al. Treatment tactics for patient with acquired hemophilia: continuous infusion of recombinant activated coagulation factor VII and the inhibitor eradication. Gematologiya I Transfusiologiya. 2022;67(2):282–94 (In Russian). DOI: 10.35754/0234-5730-2022-67-2-282-294.Ma A.D., Carrizosa D. Acquired factor VIII inhibitors: pathophysiology and treatment. Hematol Am Soc Hematol Educ Progr. 2006;432–7. DOI: 10.1182/asheducation-2006.1.432.Ma A.D., Carrizosa D. Acquired factor VIII inhibitors: pathophysiology and treatment. Hematol Am Soc Hematol Educ Progr. 2006;432–7. DOI: 10.1182/asheducation-2006.1.432.Witmer C., Young G. Factor VIII inhibitors in hemophilia A: Rationale and latest evidence. Ther Adv Hematol. 2013;4(1):59–72. DOI: 10.1177/2040620712464509.Witmer C., Young G. Factor VIII inhibitors in hemophilia A: Rationale and latest evidence. Ther Adv Hematol. 2013;4(1):59–72. DOI: 10.1177/2040620712464509.Collins P., Macartney N., Davies R., et al. A population based, unselected, consecutive cohort of patients with acquired haemophilia A. Br J Haematol. 2004;124(1):86–90. DOI: 10.1046/j.1365-2141.2003.04731.x.Collins P., Macartney N., Davies R., et al. A population based, unselected, consecutive cohort of patients with acquired haemophilia A. Br J Haematol. 2004;124(1):86–90. DOI: 10.1046/j.1365-2141.2003.04731.x.Delgado J., Jimenez-Yuste V., Hernandez-Navarro F., et al. Acquired haemophilia: Review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003;121(1):21–35. DOI: 10.1046/j.1365-2141.2003.04162.x.Delgado J., Jimenez-Yuste V., Hernandez-Navarro F., et al. Acquired haemophilia: Review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003;121(1):21–35. DOI: 10.1046/j.1365-2141.2003.04162.x.Collins P.W., Hirsch S., Baglin T.P., et al. Acquired hemophilia A in the United Kingdom: A 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ organisation. Blood. 2007;109(5):1870–7. DOI: 10.1182/blood-2006-06-029850.Collins P.W., Hirsch S., Baglin T.P., et al. Acquired hemophilia A in the United Kingdom: A 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ organisation. Blood. 2007;109(5):1870–7. DOI: 10.1182/blood-2006-06-029850.Knoebl P., Marco P., Baudo F., et al. Demographic and clinical data in acquired hemophilia A: Results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012;10(4):622–31. DOI: 10.1111/j.1538-7836.2012.04654.x.Knoebl P., Marco P., Baudo F., et al. Demographic and clinical data in acquired hemophilia A: Results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012;10(4):622–31. DOI: 10.1111/j.1538-7836.2012.04654.x.Franchini M., Capra F., Nicolini N., et al. Drug-induced anti-factor VIII antibodies: A systematic review. Med Sci Monit. 2007;13(4):RA55–61.Franchini M., Capra F., Nicolini N., et al. Drug-induced anti-factor VIII antibodies: A systematic review. Med Sci Monit. 2007;13(4):RA55–61.Oh J., Lim Y., Jang M.J., et al. Characterization of anti-factor VIII antibody in a patient with acquired hemophilia A. Blood Res. 2013;48(1):58–62. DOI: 10.5045/br.2013.48.1.58.Oh J., Lim Y., Jang M.J., et al. Characterization of anti-factor VIII antibody in a patient with acquired hemophilia A. Blood Res. 2013;48(1):58–62. DOI: 10.5045/br.2013.48.1.58.Kahle J., Orlowski A., Stichel D., et al. Frequency and epitope specificity of anti–factor VIII C1 domain antibodies in acquired and congenital hemophilia A. Blood. 2017;130(6):808–16. DOI: 10.1182/blood-2016-11-751347.Kahle J., Orlowski A., Stichel D., et al. Frequency and epitope specificity of anti–factor VIII C1 domain antibodies in acquired and congenital hemophilia A. Blood. 2017;130(6):808–16. DOI: 10.1182/blood-2016-11-751347.Клопидогрел. РЛС. Информационная система. 2026. https://www.rlsnet.ru/drugs/klopidogrel-36819Клопидогрел. РЛС. Информационная система. 2026. https://www.rlsnet.ru/drugs/klopidogrel-36819Haj M., Dasani H., Kundu S., et al. Acquired haemophilia A may be associated with clopidogrel. BMJ. 2004;329:323.Haj M., Dasani H., Kundu S., et al. Acquired haemophilia A may be associated with clopidogrel. BMJ. 2004;329:323.Shimizu T., Nogami K., Mizutani C., et al. Acquired hemophilia A with high-titer factor VIII inhibitor developing subsequent to clopidogrel administration. Rinsho Ketsuek. 2019;60:291–5. DOI: 10.11406/rinketsu.60.291.Shimizu T., Nogami K., Mizutani C., et al. Acquired hemophilia A with high-titer factor VIII inhibitor developing subsequent to clopidogrel administration. Rinsho Ketsuek. 2019;60:291–5. DOI: 10.11406/rinketsu.60.291.Hwang H., Kong J., Ju D., et al. A patient with acquired hemophilia A induced by clopidogrel. Korean J Hematol. 2012;47:80–2. DOI: 10.5045/kjh.2012.47.1.80.Hwang H., Kong J., Ju D., et al. A patient with acquired hemophilia A induced by clopidogrel. Korean J Hematol. 2012;47:80–2. DOI: 10.5045/kjh.2012.47.1.80.Liu С., Xu L., Mou P. Acquired hemophilia A induced by clopidogrel. Panminerva Med. 2024;66(3):347–9. DOI: 10.23736/S0031-0808.23.05023-1.Liu С., Xu L., Mou P. Acquired hemophilia A induced by clopidogrel. Panminerva Med. 2024;66(3):347–9. DOI: 10.23736/S0031-0808.23.05023-1.Ali N., Malik F., Jafri S. Between the devil and the deep blue sea: clopidogrelinduced acquired hemophilia A. Anticancer Res. 2016;36:6710–1.Ali N., Malik F., Jafri S. Between the devil and the deep blue sea: clopidogrelinduced acquired hemophilia A. Anticancer Res. 2016;36:6710–1.Qolbi C., Purwanto I., Anggraeni V.. Acquired Hemophilia A induced by Clopidogrel: A Case Report. Smart Med J. 2021;4(2):60–5. DOI: 10.13057/smj.v4i2. 45329.Qolbi C., Purwanto I., Anggraeni V.. Acquired Hemophilia A induced by Clopidogrel: A Case Report. Smart Med J. 2021;4(2):60–5. DOI: 10.13057/smj.v4i2. 45329.Zaman M., Pan Z., Kohli R., et al. Clopidogrel-induced acquired haemophilia A in a post-TAVR patient: a case report and literature review. Eur Hear J Case Rep. 2025;9(11):ytaf459. DOI: 10.1093/ehjcr/ytaf459.Zaman M., Pan Z., Kohli R., et al. Clopidogrel-induced acquired haemophilia A in a post-TAVR patient: a case report and literature review. Eur Hear J Case Rep. 2025;9(11):ytaf459. DOI: 10.1093/ehjcr/ytaf459.Beauverd Y., Boehlen F., Fisch L., et al. A Unique Case of Acquired Hemophilia A Presenting with Transient Ischemic Attack. Acta Haematol. 2021;144(1):88–90. DOI: 10.1159/000506273.Beauverd Y., Boehlen F., Fisch L., et al. A Unique Case of Acquired Hemophilia A Presenting with Transient Ischemic Attack. Acta Haematol. 2021;144(1):88–90. DOI: 10.1159/000506273.EACH. European Acquired Haemophilia (EACH) Registry. www.eachregistry.org.2006.EACH. European Acquired Haemophilia (EACH) Registry. www.eachregistry.org.2006.Pasquino P., Canaparo R., Capello T., et al. Acquired hemophilia A may be associated with ticagrelor therapy in a 52-year-old man after a recent percutaneous transluminal coronary angioplasty. Clin Med Insights Case Rep. 2016;9:79–81. DOI: 10.4137/CCRep.S39788.Pasquino P., Canaparo R., Capello T., et al. Acquired hemophilia A may be associated with ticagrelor therapy in a 52-year-old man after a recent percutaneous transluminal coronary angioplasty. Clin Med Insights Case Rep. 2016;9:79–81. DOI: 10.4137/CCRep.S39788.Tiede A., Worster A. Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia. Ann Hematol. 2018;97(10):1889–901. DOI: 10.1007/s00277-018-3372-z.Tiede A., Worster A. Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia. Ann Hematol. 2018;97(10):1889–901. DOI: 10.1007/s00277-018-3372-z.Tiede A., Collins P., Knoebl P., et al. International recommendations on the diagnosis hemophilia and a treatment of acquired hemophilia A. Haematologica. 2020;105(7):1791–801. DOI: 10.3324/haematol.2019.230771.Tiede A., Collins P., Knoebl P., et al. International recommendations on the diagnosis hemophilia and a treatment of acquired hemophilia A. Haematologica. 2020;105(7):1791–801. DOI: 10.3324/haematol.2019.230771.Mauser-Bunschoten E.P., De Goede-Bolder A., Wielenga J.J., et al. Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors: Experience in the Netherlands and Belgium. Neth J Med. 1998;53(6):249–55. DOI: 10.1016/S0300-2977(98)00111-9.Mauser-Bunschoten E.P., De Goede-Bolder A., Wielenga J.J., et al. Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors: Experience in the Netherlands and Belgium. Neth J Med. 1998;53(6):249–55. DOI: 10.1016/S0300-2977(98)00111-9.Rajpurkar M., Cooper D.L. Continuous infusion of recombinant activated factor VII: A review of data in congenital hemophilia with inhibitors and congenital factor VII deficiency. J Blood Med. 2018;9:227–39. DOI: 10.2147/JBM.S184040.Rajpurkar M., Cooper D.L. Continuous infusion of recombinant activated factor VII: A review of data in congenital hemophilia with inhibitors and congenital factor VII deficiency. J Blood Med. 2018;9:227–39. DOI: 10.2147/JBM.S184040.Reich L., Gatzke F., Rauchfuss S., et al. Prognostic factors for recurrence in acquired hemophilia A-results from a long-term observational study. Res Pr Thromb Haemost. 2025;9(2):102707. DOI: 10.1016/j.rpth.2025.102707.Reich L., Gatzke F., Rauchfuss S., et al. Prognostic factors for recurrence in acquired hemophilia A-results from a long-term observational study. Res Pr Thromb Haemost. 2025;9(2):102707. DOI: 10.1016/j.rpth.2025.102707.Lottenberg R., Kentro T.B., Kitchens C.S. Acquired hemophilia natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med. 1987;147:1077–81.Lottenberg R., Kentro T.B., Kitchens C.S. Acquired hemophilia natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med. 1987;147:1077–81.Mazzucconi M.G., Baldacci E., Ferretti A., et al. Acquired Haemophilia A: An intriguing disease. Mediterr J Hematol Infect Dis. 2020;12(1):1–14. DOI: 10.4084/MJHID.2020.045.Mazzucconi M.G., Baldacci E., Ferretti A., et al. Acquired Haemophilia A: An intriguing disease. Mediterr J Hematol Infect Dis. 2020;12(1):1–14. DOI: 10.4084/MJHID.2020.045.Spero J.A., Lewis J.H., Hasiba U. Corticosteroid Therapy for Acquired F VIII:C Inhibitors. Br J Haematol. 1981;48(4):635–42. DOI: 10.1111/j.1365-2141.1981.00635.x.Spero J.A., Lewis J.H., Hasiba U. Corticosteroid Therapy for Acquired F VIII:C Inhibitors. Br J Haematol. 1981;48(4):635–42. DOI: 10.1111/j.1365-2141.1981.00635.x.Green D., Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost. 1981;45(3):200–3.Green D., Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost. 1981;45(3):200–3.Collins P., Baudo F., Knoebl P., et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood. 2012;120(1):47–55. DOI: 10.1182/blood-2012-02-409185.Collins P., Baudo F., Knoebl P., et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood. 2012;120(1):47–55. DOI: 10.1182/blood-2012-02-409185.Remmington T., Smith S. Rituximab for eradicating inhibitors in people with acquired haemophilia A. Cochrane Database Syst Rev. 2021;8(8):CD011907. DOI: 10.1002/14651858.CD011907.pub3.Remmington T., Smith S. Rituximab for eradicating inhibitors in people with acquired haemophilia A. Cochrane Database Syst Rev. 2021;8(8):CD011907. DOI: 10.1002/14651858.CD011907.pub3.Tiede A., Klamroth R., Scharf R.E., et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood. 2015;125(7):1091–7. DOI: 10.1182/BLOOD-2014-07-587089.Tiede A., Klamroth R., Scharf R.E., et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood. 2015;125(7):1091–7. DOI: 10.1182/BLOOD-2014-07-587089.

The authors declare that there are no conflicts of interest present.